Sun Pharma forks over $485M to settle long-running legal battle inherited in Ranbaxy buyoutnews2022-03-24T15:38:12+00:00March 24th, 2022|Fierce Pharma|
Merck telegraphs closure of Pennsylvania antibiotics plant that employs 300news2022-03-24T14:04:24+00:00March 24th, 2022|Fierce Pharma|
Eli Lilly, Innovent hit with FDA rejection for China-developed lung cancer drug after tough reviewnews2022-03-24T13:45:06+00:00March 24th, 2022|Fierce Pharma|
AstraZeneca’s Imfinzi, chasing Merck’s Keytruda in cervical cancer, flunks key trialnews2022-03-24T13:32:32+00:00March 24th, 2022|Fierce Pharma|
Genentech suffers loss in Esbriet patent dispute with Sandoz, Teva and morenews2022-03-24T13:28:28+00:00March 24th, 2022|Fierce Pharma|
Sobi to trim staff as Pfizer manufacturing contract ends earlynews2022-03-24T12:40:44+00:00March 24th, 2022|Fierce Pharma|
Novartis’ radiotherapy Pluvicto nabs FDA approval for prostate cancer, with $2B-plus peak sales expectationsnews2022-03-24T09:42:59+00:00March 24th, 2022|Fierce Pharma|
UroGen: This year ‘critical for Jelmyto’s success,’ says Jefferiesnews2022-03-24T09:36:23+00:00March 24th, 2022|Fierce Pharma|
Precision Recruitment at Scale: Rapid ID of High-Risk Participantsnews2022-03-23T20:45:36+00:00March 23rd, 2022|Fierce Pharma|
Novartis’ Sandoz, following Pfizer’s lead, launches 2nd carcinogen-related drug recall this weeknews2022-03-23T18:55:03+00:00March 23rd, 2022|Fierce Pharma|
